SpringerLink
Log in

The Toxicology Investigators Consortium Case Registry—the 2017 Annual Report

  • Original Article
  • Published:
Journal of Medical Toxicology Aims and scope Submit manuscript

A Correction to this article was published on 01 October 2018

This article has been updated

Abstract

The Toxicology Investigators Consortium (ToxIC) Case Registry was established by the American College of Medical Toxicology in 2010. The Registry collects data from participating sites with the agreement that all bedside medical toxicology consultations will be entered. The objective of this eighth annual report is to summarize the Registry’s 2017 data and activity with its additional 7577 cases. Cases were identified for inclusion in this report by a query of the ToxIC database for any case entered from 1 January to 31 December 2017. Detailed data was collected from these cases and aggregated to provide information which includes demographics (e.g., age, gender, race, ethnicity), reason for medical toxicology evaluation (e.g., intentional pharmaceutical exposure, envenomation, withdrawal from a substance), agent and agent class, clinical signs and symptoms (e.g., vital sign abnormalities, organ system dysfunction), treatments and antidotes administered, fatality, and life support withdrawal data. Females were involved in 50.4% of cases. Transgender demographic information collection was initiated in 2017 to better represent the population and there were 36 cases involving transgender patients. Adults aged 19–65 were the most commonly reported age group. Non-opioid analgesics were the most commonly reported agent class, with acetaminophen again the most common agent reported. There were 93 fatalities reported in 2017. Treatment interventions were frequently reported with 30.6% receiving specific antidotal therapy. Major trends in demographics and exposure characteristics remained similar to past years’ reports. While treatment interventions were commonly required, fatalities were rare.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Change history

  • 01 October 2018

    Please note the Collaborators for this article listed in the Acknowledgements.

References

  1. Wax PM, Kleinschmidt KC, Brent J. ACMT ToxIC Case Registry Investigators. The Toxicology Investigators Consortium (ToxIC) Registry. J Med Toxicol. 2011;7(4):259–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Brent J, Wax PM, Schwartz T, et al. The Toxicology Investigators Consortium Case Registry—the 2010 experience. J Med Toxicol. 2011;7(4):266–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Wiegand TJ, Wax PM, Schwartz T, et al. The Toxicology Investigators Consortium Case Registry—the 2011 experience. J Med Toxicol. 2012;8(4):360–77.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Wiegand T, Wax P, Smith E, Hart K, Brent J. The Toxicology Investigators Consortium Case Registry—the 2012 experience. J Med Toxicol. 2013;9(4):380–404.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Rhyee SH, Farrugia L, Wiegand T, et al. The Toxicology Investigators Consortium Case Registry—the 2013 experience. J Med Toxicol. 2014;10(4):342–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Rhyee SH, Farrugia L, Campleman SL, et al. The Toxicology Investigators Consortium Case Registry—the 2014 experience. J Med Toxicol. 2015;11(4):388–409.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Farrugia L, Rhyee SH, Campleman SL, et al. The Toxicology Investigators Consortium Case Registry—the 2015 experience. J Med Toxicol. 2016;12(3):224–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Farrugia L, Rhyee SH, Calello DP, et al. The Toxicology Investigators Consortium Case Registry—the 2016 experience. J Med Toxicol. 2017;13(3):203–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Gummin DD, Mowry JB, Spyker DA, Brooks DE, Fraser MO, Banner W. 2016 annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 34th annual report. Clin Toxicol (Phila). 2017;55(10):1072–252.

    Article  Google Scholar 

  10. Mowry JB, Spyker DA, Brooks DE, Zimmerman A, Schauben JL. 2015 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 33rd annual report. Clin Toxicol (Phila). 2016;54(10):924–1109.

    Article  CAS  PubMed  Google Scholar 

  11. Mowry JB, Spyker DA, Brooks DE, McMillan N, Schauben JL. 2014 annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 32nd annual report. Clin Toxicol (Phila). 2015;53(10):962–1146.

    Article  CAS  Google Scholar 

  12. Center for Behavioral Health Statistics and Quality. 2016 national survey on drug use and health: detailed tables. Substance Abuse and Mental Health Services Administration, Rockville, MD 2017.

  13. Ouellette L, Cearley M, Judge B, Riley B, Jones J. Cooking with cannabis: the rapid spread of (mis)information on YouTube. Am J Emerg Med 2017.

  14. Richards JR, Smith NE, Moulin AK. Unintentional cannabis ingestion in children: a systematic review. J Pediatr. 2017;190:142–52.

    Article  PubMed  Google Scholar 

  15. Vo KT, Horng H, Li K, Ho RY, Wu AHB, Lynch KL, et al. Cannabis intoxication case series: the dangers of edibles containing tetrahydrocannabinol. Ann Emerg Med. 2018;71:306–13.

    Article  PubMed  Google Scholar 

  16. Sierzant C, Judge B. Cooking with cannabis: severe toxicity following the use of cannabutter. Clin Toxicol. 2016;54:708.

    Google Scholar 

  17. FDA (U.S. Food and Drug Administration). 2011. Neurontin® (gabapentin) capsules, Neurontin® (gabapentin) tablets, Neurontin® (gabapentin) oral solution. NDA 020235/S-036; NDA 020882/S-022; NDA 021129/S-022 FDA Approved Labeling Text dated 03/01/2011. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020235s036,020882s022,021129s022lbl.pdf; accessed 12 Feb 2018.

  18. FDA. 2012. Highlights of prescribing information: Lyrica (pregabalin) capsules, CV Lyrica (pregabalin) oral solution, CV. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021446s028lbl.pdf; accessed 12 Feb 2018.

  19. Chiappini S, Schifano F. A decade of gabapentinoid misuse: an analysis of the European Medicines Agency’s ‘Suspected Adverse Drug Reactions’ database. CNS Drugs. 2016;30(7):647–54.

    Article  PubMed  Google Scholar 

  20. Office for National Statistics [United Kingdom]. 2017. Death related to drug poisoning in England and Wales from 1993 onwards, by cause of death, sex, age and substances involved in the death. Latest release: Deaths related to drug poisoning in England and Wales: 2016 registrations, Released: 2 Aug 2017. Available: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2016registrations; accessed 12 Feb 2018.

  21. Buttram ME, Kurtz SP, Dart RC, Margolin ZR. Law enforcement-derived data on gabapentin diversion and misuse, 2002-2015: diversion rates and qualitative research findings. Pharmacoepidemiol Drug Saf. 2017;26(9):1083–6.

    Article  PubMed  Google Scholar 

  22. Bronstein AC, Spyker DA, Cantilena LR Jr, Rumack BH, Dart RC. 2011 annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 29th annual report. Clin Toxicol (Phila). 2012;50(10):911–1164.

    Article  Google Scholar 

  23. Goodman CW, Brett AS. Gabapentin and Pregabalin for pain—is increased prescribing a cause for concern? N Engl J Med. 2017;377(5):411–4. https://doi.org/10.1056/NEJMp1704633.

    Article  PubMed  Google Scholar 

  24. Johansen ME. Gabapentinoid use in the United States 2002 through 2015. JAMA Intern Med. 2018;178(2):292–4.

    Article  PubMed  Google Scholar 

  25. Smith RV, Lofwall MR, Havens JR. Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky. Am J Psychiatry. 2015;172(5):487–8.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study. PLoS Med. 2017;14(10):e1002396.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

Toxicology Investigators Consortium (ToxIC) Study Group Collaborators:

Algren DA, Alwasiyah D, Beauchamp GA, Bentur Y, Berman AJ, Beuhler MC, Biary R, Bonney C, Boyle KL, Bruccoleri RC, Burns MM, Cahana A, Cannon RD, Caravati EM, Carey J, Chiba T, Christian M, Cook MD, Cumpston K, Davis A, Dribben W, Eisenga BH, Eldos Y, Falkowitz DM, Farkas A, Finkelstein Y, Fisher E, Froberg BA, Ganetsky M, Garlich F, Geib AJ, Gittinger M, Gorodetsky R, Greene SC, Hart K, Hendrickson RG, Hernandez S, Hodgman M, Hoyte C, Judge BS, Kao L, Katz KD, Kessler BD, King JD, Kirschner RI, Kostic M, Leikin JB, Levine M, Lowry JA, Lurie Y, Majlesi N, Malashock H, Manini AF, Marino R, McKay CA Jr., McKeever R, McKeown N, Meadors K, Moore E, Morgan B, Mullins ME, Nacca NE, Niruntarai S, Nogar JN, Olmedo R, Othong R, Riley BD, Rusyniak DE, Schimmel J, Schult R, Schwarz ES, Scoccimarro A, Seifert SA, Shafer S, Smith S, Smolinske SC, Spyres M, Steck A, Stripp M, Sullivan R, Theobald J, Troendle M, Vearrier, Warrick BJ, Watts D, Wills B, Zosel AE.

We also wish to thank study coordinators AB Adefeso, D Hopkins, Julie Licata, Tammy Phan, Andrea Ramirez, Mellissa VandenBerg, and Love Wilson.

Funding

This study received funding from the NIH National Institute on Drug Abuse, 1R56DA38366 and 1R01DA037317-01, a data sharing contract with the US Food and Drug Administration and BTG International Inc. (North America).

Author information

Authors and Affiliations

  1. Hartford Hospital and University of Connecticut School of Medicine, 80 Seymour Street, Hartford, CT, 06102, USA

    Lynn A. Farrugia

  2. University of Massachusetts Medical School, 55 Lake Avenue North, LA-202, Worcester, MA, 01655, USA

    Sean H. Rhyee

  3. American College of Medical Toxicolog, 10645 N. Tatum Blvd., Suite 200-111, Phoenix, AZ, 85028, USA

    Sharan L. Campleman & Anne M. Riederer

  4. Spectrum Health Blodgett Hospital, 1840 Wealthy Street SE, Grand Rapids, MI, 49506, USA

    Bryan Judge

  5. Indiana University School of Medicine, 340 West 10th Street, Suite 6200, Indianapolis, IN, 46202, USA

    Louise Kao

  6. University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, 200 Lothrop Street, Pittsburgh, PA, 15213, USA

    Anthony Pizon

  7. Banner-University Medical Center Phoenix, 925 E. McDowell Rd, Phoenix, AZ, 85006, USA

    Lauren Porter

  8. University of Rochester Medical Center and Strong Memorial Hospital, 601 Elmwood Ave, Rochester, NY, 14642, USA

    Timothy Wiegand

  9. New Jersey Medical School, Rutgers, The State University of New Jersey, 140 Bergen Street, Suite G1600, Newark, NJ, 07101-1709, USA

    Diane Calello

  10. University of Texas Southwestern Medical School, 5323 Harry Hines Boulevard, Dallas, TX, 75390, USA

    Paul M. Wax

  11. University of Colorado School of Medicine, 13001 E 17th Pl, Aurora, CO, 80045, USA

    Jeffrey Brent

Authors
  1. Lynn A. Farrugia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sean H. Rhyee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sharan L. Campleman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bryan Judge
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Louise Kao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anthony Pizon
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lauren Porter
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Anne M. Riederer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Timothy Wiegand
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Diane Calello
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Paul M. Wax
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jeffrey Brent
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

On behalf of the Toxicology Investigators Consortium (ToxIC) Study Group

Corresponding author

Correspondence to Lynn A. Farrugia.

Ethics declarations

Conflicts of Interest

None

Previous Presentation of Data

None

Electronic Supplementary Material

ESM 1

(DOCX 32 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Farrugia, L.A., Rhyee, S.H., Campleman, S.L. et al. The Toxicology Investigators Consortium Case Registry—the 2017 Annual Report. J. Med. Toxicol. 14, 182–211 (2018). https://doi.org/10.1007/s13181-018-0679-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13181-018-0679-z

Keywords

Search

Navigation